Table 2.
Correlation of lymphocyte-predominant breast cancer (LPBC) with patient and tumor characteristics
| Characteristic | Non-LPBC | LPBC |
|---|---|---|
| Patients (n = 146), n (%) | 122 (83.6) | 24 (16.4) |
| Age, mean ± SD, years | 54.1 ± 12.8 | 54.3 ± 13.9 |
| ER, n (%) | ||
| Negative (n = 55) | 40 (72.2) | 15 (27.3) |
| Positive (n = 91) | 82 (90.1) | 9 (9.9) |
| PR, n (%) | ||
| Negative (n = 85) | 66 (77.6) | 19 (22.3) |
| Positive (n = 61) | 56 (91.8) | 5 (8.2) |
| HER2, n (%) | ||
| Negative (n = 96) | 79 (82.3) | 17 (17.7) |
| Positive (n = 50) | 43 (86) | 7 (14) |
| cT, n (%) | ||
| cT1 (n = 56) | 56 (100) | 0 (0) |
| cT2–cT4 (n = 90) | 66 (73.3) | 24 (36.7) |
| Grading, n (%) | ||
| G1–G2 (n = 41) | 38 (92.7) | 3 (7.3) |
| G3 (n = 105) | 84 (80) | 21 (20) |
SD = Standard deviation; ER = estrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2; cT = clinical staging.